The FDA has approved a once-weekly subcutaneous maintenance dose of Leqembi in an autoinjector, dubbed Leqembi IQLIK, which Eisai has hailed as a key milestone in its quest to grow the reach of the Alzheimer’s disease medicine. With a green light
read moreWegovy’s mechanism of action could be ideal for patients with more moderate disease, according to gastroenterologists and hepatologists surveyed by Spherix. More: Physician enthusiasm for Novo's Wegovy suggests 'swift' uptake in Rezdiffra-dominated MASH market: Spherix Source: fierce
read moreZydus Therapeutics has racked up a phase 2b/3 win in primary biliary cholangitis, clearing the path to a filing to establish the company as a challenger to Gilead, Intercept Pharmaceuticals and Ipsen. More: Zydus' phase 3 liver disease win tees
read moreFlying high after an FDA approval four months ago to treat generalized myasthenia gravis, Johnson & Johnson’s much-touted Imaavy has taken a hit, coming up short as part of a combination therapy in a rheumatoid arthritis trial. More: After trial
read moreAmid a growing push for more direct-to-consumer access to some of the world’s most popular drugs, Eli Lilly has inked a deal with China’s JD Health to sell its obesity, Type 2 diabetes and alopecia areata meds in the country
read morePfizer is taking a curtain call for Vyndaqel, the low-dose version of its blockbuster tafamidis franchise for the rare heart disease transthyretin amyloid cardiomyopathy (ATTR-CM). More: Pfizer to discontinue low-dose ATTR drug Vyndaqel in US ahead of 2028 patent loss
read more© 1994 - 2025 B.M. Pharmaceuticals